Is Hansa Biopharma AB halal to invest in?

As of July 2026, Hansa Biopharma AB 24H.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Hansa Biopharma AB a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hansa Biopharma AB using these criteria to determine its compliance status.

Can Muslims buy shares of Hansa Biopharma AB?

Muslim investors may consider investing in Hansa Biopharma AB if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Hansa Biopharma AB classified as NOT HALAL?

Musaffa determines the Shariah status of Hansa Biopharma AB by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Hansa Biopharma AB updated?

The Shariah compliance status of Hansa Biopharma AB may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Hansa Biopharma AB become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Hansa Biopharma AB?

You can check the latest Shariah compliance status of Hansa Biopharma AB on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Hansa Biopharma AB 24H.SG

Last Updated: Jul 13, 12:00 AM·XSTU

24H.SG Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Hansa Biopharma AB is classified as not halal.

NOT HALAL

Report Source: 2025 1st Quarter Report

Hansa Biopharma AB. Stock Analysis 24H.SG

Germany Health Care Small Cap Report: Q1, 2025

Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Key Statistics of Hansa Biopharma AB (24H.SG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€3.00€3.08

Today's Open

€3.02

Volume

8762.00

P/E Ratio (TTM)

Financial Metrics & Statements of Hansa Biopharma AB (24H.SG)

Super Investors Invested in Hansa Biopharma AB (24H.SG)

FAQ's for Hansa Biopharma AB (24H.SG)

As of July 2026, Hansa Biopharma AB 24H.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hansa Biopharma AB using these criteria to determine its compliance status.
Muslim investors may consider investing in Hansa Biopharma AB if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Hansa Biopharma AB by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Hansa Biopharma AB may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Hansa Biopharma AB on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.